Pure Global AI
NCT06155110Recruitment Completed

A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

Chinese People's Liberation Army General Hospital
Chinese PLA General HospitalPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Cardiovascular Diseases
Drug/Device/Intervention
cardiomyopeptidin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chinese PLA General Hospital
Location
Peking, China
Timeline & enrollment
Phase
Phase 4
Start date
Mar 01, 2022
End date
May 01, 2024
Enrollment
160 participants
Primary outcome

Myocardial infarct size according to MR delayed enhancement scan

Summary

This study aim to investigate the myocardium protection effect of cardiomyopeptidin in
 patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial
 enhanced MRI.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseOther ill-defined heart diseasesHeart disease, unspecifiedObservation for other suspected cardiovascular diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06155110
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06155110 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chinese PLA General Hospital and is currently Recruitment Completed. The study focuses on Cardiovascular Diseases. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.